Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Нарушения сна при болезни Паркинсона: расширение возможностей терапии
Нарушения сна при болезни Паркинсона: расширение возможностей терапии
М.Р.Нодель. Нарушения сна при болезни Паркинсона: расширение возможностей терапии. Consilium Medicum. Неврология (Прил.). 2013; 1: 33-38.
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Полный текст
Список литературы
1. Нодель М.Р., Яхно Н.Н. Нервно-психические нарушения болезни Паркинсона. Неврология. Нейропсихиатрия. Психосоматика. 2009; 2: 3–8.
2. Нодель М.Р., Русакова И.М., Яхно Н.Н. Клиническая оценка нарушений сна и бодрствования при болезни Паркинсона. Неврологический журн. 2010; 2: 19–25.
3. Shulman LM, Taback RL, Rabinstein AA, Weiner WJ. Non-recognition of depression and other non-motor symptoms in Parkinson's disease. Parkinsonism Relat Disord 2002; 8 (3): 193–7.
4. Gallagher DA, Lees AJ, Shrag A. What are the most important non-motor symptoms in patients with Parkinsons disease and are we missing them? Mov Dis 2011; 25 (15): 2493–500.
5. Tandberg E, Larsen JP, Karlsen K. Excessive daytime sleepiness and sleep benefit in Parkinson's disease: a community-based study. Mov Disord 1999; 14 (6): 922–7.
6. Rye DB, Bliwise DL. Movement disorders specific to sleep and nocturnal manifestations of movement disorders. In Movement disorders: neurologic principles and practice. Ed. by R.Watts, W.Koller. New York: McGraw-Hill, 2004; p. 855–90.
7. Comella C. Sleep disorders in Parkinsons disease: an overview. Mov Dis 2007; 22 (Suppl. 17): 367–73.
8. Larsen JP. Sleep disorders in Parkinsons disease. Adv Neurol 2003; 91: 329–4.
9. Factor SA, McAlarney T, Sanchez-Ramos JR, Wiener WJ. Sleep disorders and sleep effect in Parkinson’s disease. Mov Dis 1990; 5: 280–5.
10. Saper CB, Lu J, Chou TC et al. The hypothalamic integrator for circadian rhythms. Trend Neurosci 2005; 28: 152–7.
11. Srinivasan V, Cardinali DP, Srinivasan US et al. Therapeutic potential of melatonin and its analogs in Parkinsons disease: focus on sleep and neuroprotection. Ther Аdv Neurol Disord 2011; 4 (5): 297–317.
12. Braak H, Del Tredici K, Rub U et al. Staging of brain pathology related to sporadic Parkinsons disease. Neurology Aging 2003; 24: 197–210.
13. Beine B. Neurophysiologic basis of sleep and walkefulness. In: Fundamentals of sleep technology. Eds. N.Butkov, T.Lee-Choing. LWW. Philadelphia, 2007; p. 11–7.
14. Bordet R, Devos D, Brique S et al. Study of circadian melatonine secretion pattern at different stages of Parkinsons disease. Clin Neuropharmacol 2003; 26 (2): 65–72.
15. Fertl E, Auff E, Doppelbauer A, Waldhauser F. Circadian secretion pattern of melatonin in de novo parkinsonian patients: evidence for phase-shifting properties of l-dopa. J Neural Transm Park Dis Dement Sect 1993; 5 (3): 227–34.
16. Adi N, Mash DC, Ali E et al. Melatonin MT1 and MT2 receptors expression in Parkinsons disease. Med Sci Monit 2010; BR61–BR67.
17. Zesiewich T, Sullivan KL, Arnulf I et al. Practice parameter: treatment of nonmotor symptoms of Parkinsons disease. Neurology 2010; 74: 924–31.
18. Arnulf I, Konofal E, Merino-Andreu M et al. Parkinson's disease and sleepiness: an integral part of PD. Neurology 2002; 58 (7): 1019–24.
19. Chaudhuri KR, Pal S, DiMarco A et al. The Parkinson's disease sleep scale: a new instrument for assessing sleep and nocturnal disability in Parkinson's disease. J Neurol Neurosurg Psychiatry 2002; 73 (6): 629–35.
20. Johns MW. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep 1991; 14: 540–5.
21. Brown RG, Dittner A, Findley L et al. The Parkinson fatigue scale. Park Relat Disord 2005; 11: 49–55.
22. Peto V, Jenkinson C, Fitzpatrick R. PDQ-39: A review of the development, validation and application of a Parkinson's disease quality of life questionnaire and its associated measures. J Neurol 1998; 245 (Suppl. 1): 10–4.
23.Arnulf I, Konofal E, Merino-Andreu M et al. Parkinson's disease and sleepiness: an integral part of PD. Neurology 2002; 58 (7): 1019–24.
24. Нодель М.Р. Утомляемость при болезни Паркинсона. Журн. неврол. психиатр. им. С.С.Корсакова. 2009; 9: 23–6.
25. Brzezinski A, Vangel MG, Wurtmanc RJ. Effects of exogenous melatonin on sleep: a meta-analysis. Sleep Medicine Reviews 2005; 9: 41–50.
26. Haimov N, Lavie P, Laudon M et al. Melatonin replacement therapy of elderly insomniacs. Sleep 1995; 18 (7): 598–603.
27. Kunz D, Bes F. Melatonin as a therapy in REM sleep behavior disorder patients: an open-labeled pilot study on the possible influence of melatonin on REM-sleep regulation. Mov Disord 1999; 14: 507–11.
28. Dowling G, Mastick J, Colling E et al. Melatonin for sleep disturbances in PD. Sleep Med 2005; 6: 459–66.
29. Medeiros CA, Carvalhedo de Bruin PF, Lopes LA et al. Effect of exogenous melatonin on sleep and motor dysfunction in PD. A randomized, double blind, placebo controlled study. J Neurol 2007; 254 (4): 459–69.
30. Федорова Н.В., Никитина А.В., Губанова Е.В. Роль мелатонина в терапии первичных нарушений сна у пациентов с болезнью Паркинсона. Неврология. Ревматология. 2012; 2: 2–7.
31. Литвиненко И.В., Красаков И.В., Тихомирова О.В. Расстройства сна при неосложненной деменцией болезни Паркинсона: результаты контролируемого сравнительного исследования применения мелатонина и клоназепама. Журн. неврологии и психиатрии. 2012; 12: 26–30.
32. Нодель М.Р. Нарушения сна и бодрствования при болезни Паркинсона: комплексный подход к терапии. Неврология. Нейропсихиатрия. Психосоматика. 2012; 1: 43–8.
2. Нодель М.Р., Русакова И.М., Яхно Н.Н. Клиническая оценка нарушений сна и бодрствования при болезни Паркинсона. Неврологический журн. 2010; 2: 19–25.
3. Shulman LM, Taback RL, Rabinstein AA, Weiner WJ. Non-recognition of depression and other non-motor symptoms in Parkinson's disease. Parkinsonism Relat Disord 2002; 8 (3): 193–7.
4. Gallagher DA, Lees AJ, Shrag A. What are the most important non-motor symptoms in patients with Parkinsons disease and are we missing them? Mov Dis 2011; 25 (15): 2493–500.
5. Tandberg E, Larsen JP, Karlsen K. Excessive daytime sleepiness and sleep benefit in Parkinson's disease: a community-based study. Mov Disord 1999; 14 (6): 922–7.
6. Rye DB, Bliwise DL. Movement disorders specific to sleep and nocturnal manifestations of movement disorders. In Movement disorders: neurologic principles and practice. Ed. by R.Watts, W.Koller. New York: McGraw-Hill, 2004; p. 855–90.
7. Comella C. Sleep disorders in Parkinsons disease: an overview. Mov Dis 2007; 22 (Suppl. 17): 367–73.
8. Larsen JP. Sleep disorders in Parkinsons disease. Adv Neurol 2003; 91: 329–4.
9. Factor SA, McAlarney T, Sanchez-Ramos JR, Wiener WJ. Sleep disorders and sleep effect in Parkinson’s disease. Mov Dis 1990; 5: 280–5.
10. Saper CB, Lu J, Chou TC et al. The hypothalamic integrator for circadian rhythms. Trend Neurosci 2005; 28: 152–7.
11. Srinivasan V, Cardinali DP, Srinivasan US et al. Therapeutic potential of melatonin and its analogs in Parkinsons disease: focus on sleep and neuroprotection. Ther Аdv Neurol Disord 2011; 4 (5): 297–317.
12. Braak H, Del Tredici K, Rub U et al. Staging of brain pathology related to sporadic Parkinsons disease. Neurology Aging 2003; 24: 197–210.
13. Beine B. Neurophysiologic basis of sleep and walkefulness. In: Fundamentals of sleep technology. Eds. N.Butkov, T.Lee-Choing. LWW. Philadelphia, 2007; p. 11–7.
14. Bordet R, Devos D, Brique S et al. Study of circadian melatonine secretion pattern at different stages of Parkinsons disease. Clin Neuropharmacol 2003; 26 (2): 65–72.
15. Fertl E, Auff E, Doppelbauer A, Waldhauser F. Circadian secretion pattern of melatonin in de novo parkinsonian patients: evidence for phase-shifting properties of l-dopa. J Neural Transm Park Dis Dement Sect 1993; 5 (3): 227–34.
16. Adi N, Mash DC, Ali E et al. Melatonin MT1 and MT2 receptors expression in Parkinsons disease. Med Sci Monit 2010; BR61–BR67.
17. Zesiewich T, Sullivan KL, Arnulf I et al. Practice parameter: treatment of nonmotor symptoms of Parkinsons disease. Neurology 2010; 74: 924–31.
18. Arnulf I, Konofal E, Merino-Andreu M et al. Parkinson's disease and sleepiness: an integral part of PD. Neurology 2002; 58 (7): 1019–24.
19. Chaudhuri KR, Pal S, DiMarco A et al. The Parkinson's disease sleep scale: a new instrument for assessing sleep and nocturnal disability in Parkinson's disease. J Neurol Neurosurg Psychiatry 2002; 73 (6): 629–35.
20. Johns MW. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep 1991; 14: 540–5.
21. Brown RG, Dittner A, Findley L et al. The Parkinson fatigue scale. Park Relat Disord 2005; 11: 49–55.
22. Peto V, Jenkinson C, Fitzpatrick R. PDQ-39: A review of the development, validation and application of a Parkinson's disease quality of life questionnaire and its associated measures. J Neurol 1998; 245 (Suppl. 1): 10–4.
23.Arnulf I, Konofal E, Merino-Andreu M et al. Parkinson's disease and sleepiness: an integral part of PD. Neurology 2002; 58 (7): 1019–24.
24. Нодель М.Р. Утомляемость при болезни Паркинсона. Журн. неврол. психиатр. им. С.С.Корсакова. 2009; 9: 23–6.
25. Brzezinski A, Vangel MG, Wurtmanc RJ. Effects of exogenous melatonin on sleep: a meta-analysis. Sleep Medicine Reviews 2005; 9: 41–50.
26. Haimov N, Lavie P, Laudon M et al. Melatonin replacement therapy of elderly insomniacs. Sleep 1995; 18 (7): 598–603.
27. Kunz D, Bes F. Melatonin as a therapy in REM sleep behavior disorder patients: an open-labeled pilot study on the possible influence of melatonin on REM-sleep regulation. Mov Disord 1999; 14: 507–11.
28. Dowling G, Mastick J, Colling E et al. Melatonin for sleep disturbances in PD. Sleep Med 2005; 6: 459–66.
29. Medeiros CA, Carvalhedo de Bruin PF, Lopes LA et al. Effect of exogenous melatonin on sleep and motor dysfunction in PD. A randomized, double blind, placebo controlled study. J Neurol 2007; 254 (4): 459–69.
30. Федорова Н.В., Никитина А.В., Губанова Е.В. Роль мелатонина в терапии первичных нарушений сна у пациентов с болезнью Паркинсона. Неврология. Ревматология. 2012; 2: 2–7.
31. Литвиненко И.В., Красаков И.В., Тихомирова О.В. Расстройства сна при неосложненной деменцией болезни Паркинсона: результаты контролируемого сравнительного исследования применения мелатонина и клоназепама. Журн. неврологии и психиатрии. 2012; 12: 26–30.
32. Нодель М.Р. Нарушения сна и бодрствования при болезни Паркинсона: комплексный подход к терапии. Неврология. Нейропсихиатрия. Психосоматика. 2012; 1: 43–8.
Авторы
М.Р.Нодель
ГБОУ ВПО Первый МГМУ им. И.М.Сеченова Минздрава РФ
ГБОУ ВПО Первый МГМУ им. И.М.Сеченова Минздрава РФ
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.